chartexchange

Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewswire Inc. | Nov 12, 2026 8:00 AM EST

Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers

Read original article